Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > keep the enthusiasm in check

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 26, 2023 12:48pm

209 Views

Post# 35361278

RE:keep the enthusiasm in check

inthno - "NO" $2 Blillion is "not" reasonable given that ONCY has "de-risked" pelareorep beyond, for example, those companies that were acquired for US$2-4 Billion who were only in the pre-clinical stage of development which I have listed as examples in multiple messages beforehand. For whatever reason, you seem to be conveniently forgetting those "risk-on" deals.

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta